Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 4/20 | 0.40 |
| ▸ | GPR17 | Q13304 | 1/20 | 0.40 |
| ▸ | MTNR1A | P48039 | 2/20 | 0.40 |
| ▸ | MTNR1B | P49286 | 2/20 | 0.40 |
| ▸ | DYRK3 | O43781 | 1/20 | 0.39 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.39 |
| ▸ | DYRK2 | Q92630 | 1/20 | 0.39 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.39 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.39 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.39 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.39 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.39 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.39 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.38 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3711669 | 0.94 | CYP19A1 (0.42) | CYP19A1GPR17MTNR1AMTNR1BDYRK3 | |
| SCHEMBL4568424 | 0.92 | KDM4E (0.43) | CYP19A1MTNR1AMTNR1BMAPK13MAPK12 | |
| SCHEMBL4568538 | 0.91 | TUBB4A (0.41) | CYP19A1GPR17DYRK3DYRK1ADYRK2 | |
| SCHEMBL4568229 | 0.90 | CYP19A1 (0.41) | CYP19A1GPR17DYRK3DYRK1ADYRK2 | |
| SCHEMBL3704285 | 0.90 | GPR17 (0.43) | CYP19A1GPR17MTNR1AMTNR1BDYRK3 | |
| SCHEMBL3711070 | 0.89 | CYP19A1 (0.51) | CYP19A1GPR17MTNR1AMTNR1BMAPK13 | |
| SCHEMBL3712236 | 0.88 | MAPK13 (0.52) | CYP19A1GPR17MAPK13MAPK12MAPK11 | |
| SCHEMBL4568208 | 0.88 | MDM4 (0.44) | CYP19A1GPR17MTNR1AMTNR1BPTGS2 | |
| SCHEMBL3704461 | 0.88 | GPR17 (0.44) | GPR17MTNR1AMTNR1BMAPK13MAPK12 | |
| SCHEMBL4568218 | 0.87 | CYP19A1 (0.51) | CYP19A1GPR17ENPP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2474530-B1 | INDOLE DERIVATIVE AND PHARMACOLOGICALLY ACCEPTABLE SALT THEREOF | KISSEI PHARMACEUTICAL (JP) | 2014-09-03 | — | — | EP | disclosed |
| US-20120122931-A1 | INDOLE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2012-05-17 | — | — | US | disclosed |
| US-20120122931-A1 | INDOLE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2012-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120122931-A1 | INDOLE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | PTGER1, CYSLTR1, LTB4R | CYP19A1 1262/4885GPR17 59/4885MTNR1A 19/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.